Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Iterum Therapeutics PLC (ITRM)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Iterum Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1.540 -0.040    -2.53%
31/12 - Closed. Currency in USD ( Disclaimer )
After Hours
1.540
0.000
0.000%
19:46:48 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 98,562
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.500 - 1.630
Iterum Therapeutics 1.540 -0.040 -2.53%

ITRM User Rankings

 
Users ranking according to the performance of their sentiments for the Iterum Therapeutics PLC stock.
RankUsernameTotalClosedWinningWin %Chg. %
1Federico Mattei111100+100%
2An Truong111100+87.63%
3Riccardo Fava1000+49.09%
4Juan Soto Rios111100+7.74%
5HusinKristal111100+1.7%
6Roger Neves11000%
7Nikolay Dzhalov1100-3.82%
8martjan schot1000-6.82%
9Rob AKaas1100-7.23%
10雪 袁1100-8.88%
11John Smith1100-27.44%
12Stefano Stanzani1100-32.43%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ITRM Comments

Write your thoughts about Iterum Therapeutics PLC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ramon Pradere
Ramon Pradere Jan 30, 2023 3:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
any news
Reply
0 0
Report
Patient Guy
Patient Guy Nov 05, 2021 9:03AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ITRM today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
Reply
1 2
Report
Prince Khan
Prince Khan Sep 29, 2021 12:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Should buy or not
Reply
1 0
Report
Patient Guy
Patient Guy Sep 29, 2021 12:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I have !
Reply
0 0
Report
Bruce Wayne
Bruce Wayne Sep 29, 2021 12:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy.
Reply
0 0
Report
Patient Guy
Patient Guy Sep 29, 2021 8:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced a data presentation at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021.Title: In Vitro Antibacterial Susceptibility Testing of Sulopenem Against Category A and B Bio-threat Bacterial Pathogens
Reply
0 0
Report
Patient Guy
Patient Guy Sep 29, 2021 8:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This study is not listed in their pipeline. But I suppose the news must be good.......
Reply
0 0
Report
Patient Guy
Patient Guy Sep 29, 2021 8:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ITRM today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTI). In July, the Company announced that it had received a Complete Response Letter (CRL) from the FDA requesting additional data to support approval of oral sulopenem for the treatment of adult women with a uUTI. “We had a successful meeting with the FDA and have established various potential paths forward to address the request in the CRL for additional data in support of our NDA,” said Corey Fishman, Chief Executive Officer. “We are currently evaluating the optimal design for an additional Phase 3 uUTI study to be conducted prior to the potential resubmission of the NDA. We continue to believe in the ability of sulopenem to treat the growing problem of multi-drug resistant UTIs in the community.”. Iterum notes that cash, cash equivalents and short-term investments were $91.5 million at the end of the second quarter of 2021. Based on the current operating plan and subject to final determination of the design and planned conduct of additional clinical and potential nonclinical development for sulopenem, the Company believes that it is well positioned financially to fund its operations into the second half of 2023.
Reply
0 0
Report
Faster Hamed
Faster Hamed Aug 13, 2021 12:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Iterum Therapeutics (ITRM): Q2 Non-GAAP EPS of -$0.04 beats by $0.02; GAAP EPS of $0.04 beats by $0.11.Cash, cash equivalents and short-term investments of $91.44M.Press Release“Despite...
Reply
3 0
Report
Ramez Khalil
Ramez Khalil Aug 13, 2021 9:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Good news on the way
Reply
4 0
Report
Bruce Wayne
Bruce Wayne Aug 13, 2021 9:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what good news?
Reply
0 0
Report
Tariq AlZadjali
Tariq AlZadjali Aug 10, 2021 2:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Any one can analyse here plz
Reply
1 0
Report
Faster Hamed
Faster Hamed Aug 10, 2021 2:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i can analyse ... how i can help you ? 🤭
Reply
0 0
Report
Patient Guy
Patient Guy Aug 10, 2021 3:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
"the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Friday, August 13, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business." - Before the open, this might be a good omen.
Reply
1 0
Report
Faster Hamed
Faster Hamed Aug 10, 2021 3:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
news source plz ?
Reply
0 0
Report
Patient Guy
Patient Guy Aug 10, 2021 3:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ITERUm investor relations page
Reply
0 0
Report
Faster Hamed
Faster Hamed Aug 10, 2021 3:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Patient Guy thanks bro
Reply
0 0
Report
Grant Garrett
Grant Garrett Aug 02, 2021 9:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hold... and wait for the homerun pay day when it hits 2.50
Reply
3 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email